|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM150133421 |
| 003 |
DE-627 |
| 005 |
20231223053227.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0501.xml
|
| 035 |
|
|
|a (DE-627)NLM150133421
|
| 035 |
|
|
|a (NLM)15334890
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Mugiya, Soichi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravesical Bacillus Calmette-Guerin (BCG
|b Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.09.2004
|
| 500 |
|
|
|a Date Revised 15.11.2006
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We performed a study to evaluate the usefulness of intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation on carcinoma in situ (CIS) of the bladder. Between 1998 and 2003, 43 patients were treated for CIS of the bladder with a median follow-up period of 45 months (range: 12 to 69 months). The patients (35 males and 8 females) ranged in age from 45 to 89 years (average: 67.5 years). They underwent intravesical instillation of 40 mg of BCG once a week for 6 weeks. A complete response (CR) was achieved in 83.7% of the patients. Among these patients, 97.2% and 70.7% remained recurrence-free during follow up for one year and three years, respectively. The median duration of CR was 31.5 months. Although total cystectomy was performed on 1 patient, none of the patients died of bladder cancer. Adverse effects included bladder irritability in 48.8%, pyuria in 46.5%, gross hematuria in 18.6%, and fever (temperature over 37.5 degrees C) in 9.3%. No clinically significant side effects were observed. These results indicate that intravesical instillation of BCG at a dose of 40 mg given 6 times was as effective as the routine dose of 80 mg, and could decrease systemic adverse effects such as high fever
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a BCG Vaccine
|2 NLM
|
| 700 |
1 |
|
|a Nagata, Masao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takayama, Tatsuya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ozono, Seiichiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ito, Toshiki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Maruyama, Satoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hadano, Shinsuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nagae, Hiroshi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 50(2004), 7 vom: 01. Juli, Seite 469-73
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:50
|g year:2004
|g number:7
|g day:01
|g month:07
|g pages:469-73
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 50
|j 2004
|e 7
|b 01
|c 07
|h 469-73
|